POSEIDA THERAPEUTICS INC (PSTX)
US73730P1084 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 49.34M | 44.47M | 81.40M | 206.30M | 84.00M | |||
| Marketable Securities | 181.51M | 167.73M | 201.10M | 0.00 | 225.20M | |||
| Receivables | 14.75M | 9.01M | 9.10M | N/A | N/A | |||
| Other Current Assets | 5.10M | 5.26M | 7.00M | 7.50M | 4.80M | |||
| Total Current Assets | 250.70M | 226.47M | 298.60M | 213.90M | 314.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 36.42M | 40.78M | 46.70M | 48.20M | 48.30M | |||
| Goodwill | 4.23M | 4.23M | 4.20M | 4.20M | 4.20M | |||
| Intangibles | 1.32M | 1.32M | 1.30M | 1.30M | 1.30M | |||
| Other Non-Current Assets | 905.00K | 1.08M | 1.10M | 1.70M | 3.60M | |||
| Total Non-Current Assets | 42.87M | 47.41M | 53.20M | 55.40M | 57.50M | |||
| TOTAL ASSETS | 293.58M | 273.88M | 351.80M | 269.30M | 371.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | 0.00 | |||
| Accrued Expenses | 31.46M | 33.65M | 28.00M | 27.40M | 27.40M | |||
| Accounts Payable | 5.20M | 3.27M | 2.20M | 9.00M | 800.00K | |||
| Other Current Liabilities | 41.61M | 34.40M | 23.60M | 7.00M | 1.80M | |||
| Total Current Liabilities | 78.27M | 71.32M | 53.90M | 43.30M | 30.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 58.91M | 58.59M | 58.30M | 29.40M | 29.10M | |||
| Deferred Taxes/Income | N/A | N/A | 100.00K | 100.00K | 100.00K | |||
| Other Non-Current Liabilities | 69.19M | 40.28M | 52.10M | 40.40M | 50.30M | |||
| Total Non-Current Liabilities | 128.10M | 98.87M | 110.30M | 69.80M | 79.50M | |||
| TOTAL LIABILITIES | 206.37M | 170.18M | 164.20M | 113.10M | 109.50M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -629.70M | -594.29M | -470.90M | -406.90M | -281.90M | |||
| Additional Paid In Capital | 716.53M | 697.86M | 658.60M | 563.10M | 543.80M | |||
| Common Shares | 10.00K | 10.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 376.00K | 126.00K | -100.00K | N/A | N/A | |||
| Shares Outstanding | 97.41M | 95.64M | 86.00M | 62.50M | 61.90M | |||
| Tangible Book Value per Share | 0.84 | 1.03 | 2.12 | 2.41 | 4.14 | |||
| Total Shareholders' Equity | 87.21M | 103.70M | 187.60M | 156.20M | 262.00M | |||
| TOTAL LIABILITIES AND EQUITY | 293.58M | 273.88M | 351.80M | 269.30M | 371.50M | |||
| Statistics | ||||||||
| Debt/Equity | 0.68 | 0.56 | 0.31 | 0.19 | 0.11 | |||
| Current Ratio | 3.20 | 3.18 | 5.54 | 4.94 | 10.47 | |||
| Return On Assets (ROA) | -20.70% | -45.07% | -18.19% | -46.42% | -34.94% | |||
| Return On Equity (ROE) | -69.67% | -119.02% | -34.12% | -80.03% | -49.54% | |||
All data in USD , ROIC based on taxRate of 0.21